Evidence map›Paper›PMID 32639897›Full record

ArticlePublic health reports (Washington, D.C. : 1974)

A National Measurement Framework to Assess and Improve Sickle Cell Care in 4 US Regions.

Elissa Z Faro, Lisa Shook, Marsha J Treadwell, Allison A King, Lauren N Whiteman, E Donnell Ivy, Mary Hulihan, Patricia L Kavanagh, Sabrina Selk, Suzette Oyeku and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health reports (Washington, D.C. : 1974). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elissa Z FaroAlbert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0001-5910-4056
Lisa Shook2518 Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Marsha J Treadwell6164 Department of Hematology/Oncology, UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.
Allison A King12275 Washington University School of Medicine, St Louis, MO, USA.
Lauren N Whiteman116031 Washington/Baltimore High Intensity Drug Trafficking Areas Program, George Mason University, Fairfax, VA, USA.
E Donnell Ivy374349 Hemoglobinopathies Programs, Genetic Services Branch, Division of Services for Children With Special Health Needs, Maternal and Child Health Bureau, Health Resources and Services Administration, Washington, DC, USA.
Mary Hulihan1242 Epidemiology and Surveillance Branch, Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Patricia L Kavanagh12259 Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA.
Sabrina Selk1854 Office of Health Equity, Massachusetts Department of Public Health, Boston, MA, USA.
Suzette OyekuAlbert Einstein College of Medicine, Bronx, NY, USA.
Scott D Berns50980 National Institute for Children's Health Quality, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCoordinated measurement strategies are needed to inform collaborative approaches to improve access to and quality of care for persons with sickle cell disease (SCD). The objective of our study was to develop a multilevel measurement strategy to assess improvements in access to and quality of care for persons with SCD in 4 US regions.

methodsFrom 2014 through 2017, regional grantees in the Sickle Cell Disease Treatment Demonstration Program collected administrative and patient-level electronic health record (EHR) data to assess quality improvement initiatives. Four grantees-covering 29 US states and territories and an SCD population of 56 720-used a collective impact model to organize their work. The grantees collected administrative data from state Medicaid and Medicaid managed care organizations (MCOs) at multiple points during 2014-2017 to assess improvements at the population level, and local patient-level data were abstracted from site-level EHRs at regular intervals to track improvements over time.

resultsAdministrative data were an important source of understanding population-level improvements but were delayed, whereas patient-level data were more sensitive to small-scale quality improvements.

conclusionsWe established a shared measurement approach in partnership with Medicaid and Medicaid MCO stakeholders that can be leveraged to effectively support quality improvement initiatives for persons with SCD in the United States.

Indexed as

Practice Guidelines as TopicAnemia, Sickle CellDelivery of Health CareHumansQuality ImprovementUnited Statesadministrative datacollective impactmeasurementquality improvementsickle cell disease

Identifiers

PMID32639897
PMCPMC7383758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.